AstraZeneca said on Tuesday its study of monoclonal antibody AZD7442 did not meet the main goal of preventing symptomatic COVID-19 in people recently exposed to the SARS-CoV-2 virus.
Comments
The commenter agrees to the privacy policy of Ynet News and agrees not to submit comments that violate the terms of use, including incitement, libel and expressions that exceed the accepted norms of freedom of speech.
